| Caplacizumab for acquired thrombotic thrombocytopenic purpura F Peyvandi, M Scully, JA Kremer Hovinga, S Cataland, P Knöbl, H Wu, ... New England Journal of Medicine 374 (6), 511-522, 2016 | 600 | 2016 |
| CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells S Jähnichen, C Blanchetot, D Maussang, M Gonzalez-Pajuelo, KY Chow, ... Proceedings of the National Academy of Sciences 107 (47), 20565-20570, 2010 | 276 | 2010 |
| Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs H Ulrichts, K Silence, A Schoolmeester, P de Jaegere, S Rossenu, ... Blood 118 (3), 757-765, 2011 | 205 | 2011 |
| The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis M Van Roy, C Ververken, E Beirnaert, S Hoefman, J Kolkman, ... Arthritis research & therapy 17 (1), 1-16, 2015 | 197 | 2015 |
| Shielding of the A1 domain by the D′ D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V H Ulrichts, M Udvardy, PJ Lenting, I Pareyn, N Vandeputte, ... Journal of Biological Chemistry 281 (8), 4699-4707, 2006 | 176 | 2006 |
| Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura F Callewaert, J Roodt, H Ulrichts, T Stohr, WJ van Rensburg, S Lamprecht, ... Blood 120 (17), 3603-3610, 2012 | 155 | 2012 |
| Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1 JFW Keuren, SJH Wielders, H Ulrichts, T Hackeng, JWM Heemskerk, ... Arteriosclerosis, thrombosis, and vascular biology 25 (7), 1499-1505, 2005 | 107 | 2005 |
| Reperfusion of cerebral artery thrombosis by the GPIb–VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs S Momi, M Tantucci, M Van Roy, H Ulrichts, G Ricci, P Gresele Blood 121 (25), 5088-5097, 2013 | 83 | 2013 |
| Identification of Residues within Human Glycoprotein VI Involved in the Binding to Collagen EVIDENCE FOR THE EXISTENCE OF DISTINCT BINDING SITES C Lecut, V Arocas, H Ulrichts, A Elbaz, JL Villeval, JJ Lacapère, ... Journal of Biological Chemistry 279 (50), 52293-52299, 2004 | 83 | 2004 |
| The von Willebrand factor self‐association is modulated by a multiple domain interaction H Ulrichts, K Vanhoorelbeke, JP Girma, PJ Lenting, S Vauterin, ... Journal of Thrombosis and Haemostasis 3 (3), 552-561, 2005 | 66 | 2005 |
| Inhibition of platelet glycoprotein Ib and its antithrombotic potential K Vanhoorelbeke, H Ulrichts, GV de Walle, A Fontayne, H Deckmyn Current pharmaceutical design 13 (26), 2684-2697, 2007 | 62 | 2007 |
| Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs K Vanhoorelbeke, H Ulrichts, A Schoolmeester, H Deckmyn Current Drug Targets-Cardiovascular & Hematological Disorders 3 (2), 125-140, 2003 | 61 | 2003 |
| Von Willebrand factor but not α-thrombin binding to platelet glycoprotein Ibα is influenced by the HPA-2 polymorphism H Ulrichts, K Vanhoorelbeke, S Cauwenberghs, S Vauterin, H Kroll, ... Arteriosclerosis, thrombosis, and vascular biology 23 (7), 1302-1307, 2003 | 59 | 2003 |
| Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIbα L Pontiggia, B Steiner, H Ulrichts, H Deckmyn, M Forestier, JH Beer Thrombosis and haemostasis 96 (6), 774-780, 2006 | 47 | 2006 |
| Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention O Muller, M Hamilos, J Bartunek, H Ulrichts, F Mangiacapra, JB Holz, ... The American journal of cardiology 105 (3), 333-338, 2010 | 45 | 2010 |
| Role of glycoprotein Ibα in phagocytosis of platelets by macrophages BA Badlou, G Spierenburg, H Ulrichts, H Deckmyn, WM Smid, ... Transfusion 46 (12), 2090-2099, 2006 | 42 | 2006 |
| Platelet antigens and their function H Deckmyn, H Ulrichts, G Van de Walle, K Vanhoorelbeke Vox sanguinis 87 (s2), 105-111, 2004 | 41 | 2004 |
| The GPIbα–thrombin interaction: far from crystal clear K Vanhoorelbeke, H Ulrichts, RA Romijn, EG Huizinga, H Deckmyn Trends in molecular medicine 10 (1), 33-39, 2004 | 37 | 2004 |
| Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs SF De Meyer, K Vanhoorelbeke, H Ulrichts, S Staelens, HB Feys, I Salles, ... Cardiovascular & Haematological Disorders-Drug Targets (Formerly Current …, 2006 | 33 | 2006 |
| The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention JE van Loon, PPT de Jaegere, H Ulrichts, HHDM van Vliet, MPM de Maat, ... Thrombosis and haemostasis 106 (1), 165-171, 2011 | 28 | 2011 |
